// App-Quantinova.ai

e15074 : Delayed toxicities with anti-PD-1 and anti-PDL-1 immune checkpoint inhibitors (ICIs).

Researchers

Presenter

  • Neil J. Shah

Principal Investigators

  • Barbara T Ma

  • William J Kelly

  • Anas Belouali

  • Michael T Serzan

  • Sebastian Ochoa Gonzalez

  • Bradley Colton

  • Megan M Janni

  • Alice R Knoedler

  • Matthew Blackburn

  • Jeevan Puthiamadathil

  • Subha Madhavan

  • Pallavi P. Kumar

  • Stephen V. Liu

  • Geoffrey Thomas Gibney

  • Michael B. Atkins

Medical Centers

  • Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

  • Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC

  • Innovation Center for Biomedical Informatics, Georgetown University Medical Center, Washington, DC

  • Georgetown University, Washington, DC

  • The Harry and Jeanette Weinberg Cancer Inst, Baltimore, MD

  • Georgetown University Medical Center, Washington, DC

  • Moffitt Cancer Center, Tampa, FL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Atezolizumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved